In 2008, Eridanus launched their Brand Division when acquiring exclusive development & commercialization rights to, two early-phase, novel, proprietary compounds in the area of oncology. This division within Eridanus is focused on New Chemical Entities (NCEs), which provide for unmet medical needs. We’re dedicated to building our branded product portfolio through internal development; as well as, licensing & acquisition. Through our worldwide strategic alliances, these products will be distributed and/or licensed on a worldwide, or territory-specific basis.
In 2009, to expand our portfolio of products, Eridanus entered into an agreement with an overseas pharmaceutical company to represent their proprietary products in North America. Through this agreement, we will select specific products to develop internally, while simultaneously, identifying partners to co-develop/sub-license the remaining products.
In May 2009, Eridanus entered into an exclusive license agreement with a US-based company to identify Asian partners for an OB/GYN product, which is currently under development in North America.
In 2013, our Brand Division was relocated to Kansas City, Kansas. Expansion is currently ongoing, in anticipation of adding needed support to carryout more brand activities including: the acquisition of an NDA indicated for maintenance therapy of acute lymphatic leukemia, a 505(b)(2) with various oncological indications.
Eridanus core, branded therapeutic categories include: oncology, CNS, GI, cardiovascular, and certain orphan indications.